Spyre Therapeutics, Inc.
SYRE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,094,803 | $148,425 | $37,926 | $312,287 |
| - Cash | $89,423 | $188,893 | $34,863 | $15,142 |
| + Debt | $0 | $84,555 | $4,629 | $5,060 |
| Enterprise Value | $1,005,380 | $44,087 | $7,692 | $302,205 |
| Revenue | $0 | $886 | $2,329 | $18,739 |
| % Growth | -100% | -62% | -87.6% | – |
| Gross Profit | $0 | $886 | $2,329 | $18,739 |
| % Margin | – | 100% | 100% | 100% |
| EBITDA | -$207,967 | -$127,600 | -$82,817 | -$64,073 |
| % Margin | – | -14,401.8% | -3,555.9% | -341.9% |
| Net Income | -$208,018 | -$338,790 | -$83,815 | -$65,801 |
| % Margin | – | -38,238.1% | -3,598.8% | -351.1% |
| EPS Diluted | -3.18 | -46.15 | -24.86 | -25.02 |
| % Growth | 93.1% | -85.6% | 0.6% | – |
| Operating Cash Flow | -$157,410 | -$99,910 | -$80,144 | -$53,716 |
| Capital Expenditures | $0 | $0 | -$38 | -$573 |
| Free Cash Flow | -$157,410 | -$99,910 | -$80,182 | -$54,289 |